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Purpose: Aerobic exercise (AE) lowers blood pressure (BP) 5-7 mmHg among those with hypertension, 
but there is considerable variability in the BP response to AE. Genetic predispositions account for 40-65% 
of this variability; however, identifying genetic variants that associate with the BP response to AE is a 
challenge. We performed a meta-analysis to integrate the small number of studies that examined the 
influence of candidate genes on the BP response to AE. Methods: Studies retrieved included an acute or 
chronic AE intervention; BP before and after AE by genotype; and candidate gene polymorphisms. Effect 
sizes were the standardized mean difference of BP post-vs. pre-exercise for AE training interventions, and 
post-vs. pre-exercise BP vs. control for acute AE interventions. Effect sizes were disaggregated for 
genotype and adjusted for baseline sample features. Analyses followed fixed-effects assumptions. Results: 
11 AE training (N=2646) and 4 acute AE (N=50) studies qualified. AE training interventions were 
performed at 62.3±7.5% (Mean+SD) maximum oxygen consumption for 43.8±11.6 min⋅session-1, 3.6±1.2 
d⋅wk-1 for 15.3±7.6 wk. Participants were mostly non-Hispanic white (N=1,736) men (N=1,278) and 
women (N=1,360), 44.2±10.7 yr with a BP of 134.4±11.9/78.6±9.3 mmHg and body mass index of 
26.9±2.6 kg.m-2.The effect of exercise on the BP response to AE training was small but statistically 
significant for systolic BP (SBP) (d+ = -0.21 [95% CI = -0.247, -0.168], -3.1 mmHg, I2=77.8%) and 
diastolic BP (DBP) (d+ = -0.20 [95% CI = -0.235, -0.158], -1.9 mmHg, I2=62.2%). Sample features 
explained 59.1-71.5% of the variability in the BP response to AE training (P< 0.001), and reductions were 
greater among samples that had a higher resting BP (SBP: β = -0.68, P< 0.001; DBP: β=-0.56, P=0.01), 
that were younger (SBP: β=0.34, P<0.01; DBP: NS, P>0.05), and that included more women than men 
(SBP: β = 0.41, P<0.001; DBP: β=0.52, P<0.001. Only the angiotensinogen (AGT) M235T (rs699) 
polymorphism showed a significant association with the DBP response to AE training (Multiple R=0.058, 
P=0.02), explaining 0.3% of the variability in the DBP response. Pairwise comparisons of AGT M235T 
genotypes showed those with the AGT MM genotype reduced DBP 2.9 mmHg more in response to AE 
training compared to those with the AGT TT genotype (Multiple R=0.076, P=0.02). Acute interventions 
were performed at 50.1±10.1% maximum oxygen consumption for 40 min·session-1. Participants were men, 
44.1±1.0 yr with a BP of 145.7±1.7 / 85.8±0.9 mmHg and body mass index of 29.9±0.3 kg.m-2. BP 
responses to acute AE were large and heterogeneous for SBP (d+ = -0.62 [95% CI = -0.75, -0.50], -5.5 
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mmHg, I2 =48%), and small and homogeneous for DBP (d+ =-0.28 [95% CI = -0.40, -0.16], -1.7 mmHg, I2 
=0%). Sample features explained 55.2-82.3% of the variability in the BP response to acute AE (P< 0.001), 
while candidate gene polymorphisms explained a marginally significant 4.6-6.0% of the variability 
(P=0.08). Analyses of individual polymorphisms were not feasible due to the low numbers of interventions 
and observations. Conclusions: Despite our attempt to increase the sample size to detect polymorphism 
associations with the BP response to AE, sample features explained most of the variability across trials, 
although the AGT M235T polymorphism is promising. These findings reinforce the notion that most 
genetic variants explain only a small amount of variability in the response of health/fitness phenotypes to 
exercise, if any. Future research efforts seeking to explain the variability of health/fitness phenotypes to 
exercise such as BP should explore sample features known to influence the phenotype of interest, as well as 
the multiple levels of gene regulation using high throughput screening in larger, more ethnically diverse 


















Hypertension (HTN) is a major public health issue in the United States (US) 
affecting an estimated 77.9 million US adults (33.3%) 20 years of age and older (Go et 
al., 2013; JNC VII, 2003) [Table 1]. In addition, HTN is a major independent risk factor 
for cardiovascular disease (CVD) and is the most common primary diagnosis in the US 
(Go et al., 2013). The prevalence of HTN is higher in men (16.8%) than women (12.2%) 
until 45 years, similar from 45 to 64 years (44.0%), and higher in women (75.5%) than 
men (68.0%) after 64 years (Go et al., 2013). The prevalence among blacks (41.3%) is 
higher than whites (28.9%), especially among black (47.0%) versus white (30.7%) 
women (Go et al., 2013). Therefore, due to its significant impact on US public health, the 
prevention, treatment, and control of HTN has become a major public health priority 
(Pescatello, 2010).    
Table 1: Classification of blood pressure among adults (JNC VII, 2003) 
Blood Pressure Classification SBP (mmHg) DBP (mmHg) 
Normal < 120 and < 80 
Prehypertension 120-139 or 80-89 
Stage 1 Hypertension 140-159 or 90-99 
Stage 2 Hypertension A 160 or ≥ 100 
Stage 3 Hypertension ≥ 180 or ≥ 110 
Abbreviations. SBP, systolic blood pressure; DBP, diastolic blood pressure; mmHg, millimeters of mercury. 
Aerobic exercise (AE) is an effective lifestyle therapy to prevent, treat, and 
control HTN because it reduces BP 5-7 mmHg among those with HTN  
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(Pescatello et. al., 2004). Evidence shows BP reductions of this magnitude can lower the 
risk of developing CVD by 20-30% (JNC VII, 2003). Therefore, the American College of 
Sports Medicine (ACSM) recommends a Frequency, Intensity, Time and Type (FITT) 
exercise prescription (Ex Rx) for HTN of AE performed at moderate intensity (40-60% of 
maximum oxygen reserve [VO2R]) for 30-60 minutes, on most preferably all days of the 
week that is supplemented by resistance exercise (Pescatello et. al., 2004; Thompson, 
Gordon, Pescatello, & American College of Sports Medicine, 2009).  
Statement of the Problem 
 
 Despite the ACSM FITT Ex Rx to prevent, treat, and control HTN [Table 2], 
there is considerable variation in the BP response to exercise, with 25% of the people 
with HTN not lowering their BP with exercise (Hagberg, Park, & Brown, 2000). 
Bouchard and Rankinen (2001) examined the inter-individual variation in the BP 
response to a standardized 20 week AE training program among 481 sedentary, adult 
Caucasians from 98 two-generation families as part of the HEalth, RIsk factors, exercise 
Training And GEnetics (HERITAGE) family study. They found although there was an 
average systolic BP (SBP) post training reduction of 8.2 ± 11.6 mmHg, a considerable 
amount of heterogeneity remained with some subjects experiencing significant SBP 
decreases (> 40 mmHg) and other subjects experiencing significant SBP increases (> 20 
mmHg) (Bouchard & Rankinen, 2001; Bouchard et al., 2012). In addition, the standard 
deviation of the mean BP response to AE training exceeded the mean value itself, further 
supporting the inference of heterogeneity in the BP response to exercise. These findings 
suggest that there are environmental and genetic components that contribute to the 
inter-individual variation observed in the BP response to AE, with heritability estimates 
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of approximately 40-65% across generations (Bouchard & Rankinen, 2001; Bouchard et 
al., 2012). 
Table 2: ACSM FITT Ex Rx for Hypertension (Thompson et al., 2009) 
Frequency  On most, preferably all days of the week 
700 - > 2,000 kcal·wk-1 
Intensity 40-60% VO2R or HRR 
64-84% HRmax 
Borg RPE 11-14 
Time 30-60 m·d-1 continuous or accumulated 
Type Aerobic supplemented by resistance exercise 
 
Abbreviations. HRmax, heart rate max; HRR, heart rate reserve; kcal•wk-1, kilocalories per week; m•d-1, minutes 
per day; RPE, rating of perceived exertion; VO2R, maximal oxygen consumption reserve. 
 
Candidate gene studies aim to identify whether an association exists between a 
specific genetic variant and health/fitness phenotype such as the BP response to exercise. 
Presently, 26 different candidate gene polymorphisms have been reported to be 
associated with the BP response to AE (Alioglu et al., 2010; Augeri et al., 2009; 
Blanchard et al., 2006; Delmonico et al., 2005; de Luis et al., 2006; Feairheller et al., 
2009; Flavell et al., 2006; Franks et al., 2004; Friedl, Krempler, Sandhofer, & Paulweber, 
1996 ;Grove et al., 2007; Hagberg, Ferrell, Dengel, & Wilund, 1999; Hautala et al., 2006; 
Jones et al., 2006; Kilpelainen et al., 2008; Kimura et al., 2003; Macho-Azcarate, Marti, 
Calabuig, & Martinez, 2002; Ortlepp et al., 2003; Pescatello et al., 2007a; Pescatello et 
al., 2007b; Pescatello et al., 2009; Rankinen et al., 2000; Rankinen et al., 2002; Rankinen 
et al., 2007; Rauramaa, et al. 2002; Rivera et al., 2001; Takakura et al., 2006; Vargas et 
al., 2013; Zateyschikov, 2007 et al.; Zhang etal., 2002) [Appendix A]. These 
polymorphisms include those involved with: 1) Renin Angiotensin System (RAS) and/or 
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Renal Function [angiotensin converting enzyme (ACE) (rs4340), adducin 1 alpha (ADD1) 
(rs4961), angiotensinogen (AGT) (rs699), angiotensin 2 type 1 receptor (AGTR1) 
(rs5186), and aldosterone synthase (CYP11B2) (rs1799998); 2) Sympathetic Nervous 
System [adenosine monophosphate deaminase 1 (AMPD1) (rs17602729), adrenergic 
receptor, beta 1 (ADRB1) (rs1801253), adrenergic receptor, beta 2 (ADRB2) (rs1042714), 
cholinergic receptor (CHRM2) (rs324640, rs8191992), guanine nucleotide binding 
protein system alpha subunit (GNAS) (rs7121), and guanine nucleotide binding protein, 
beta polypeptide 3 (GNB3) (rs5443)]; and 3) Nitric Oxide Synthase Pathway and/or 
Vascular Function [endothelin 1 (EDN1) (rs5370, rs2070699, rs5369), endothelial nitric 
oxide synthase (NOS3) (rs2070744), and transforming growth factor, beta 1 (TGFB1) 
(rs1800470)]. Other polymorphisms identified as established and emerging 
cardiovascular disease risk factors implicated with the etiology of HTN include:1) 
Dyslipidemia [apolipoprotein (APOE) (rs7412, rs429358), fatty acid binding protein 2 
(FABP2) (rs1799883), and lipoprotein lipase (LPL) (rs328)]; 2) Obesity [leptin receptor 
(LEPR) (rs1137100)]; and 3) Inflammatory Biomarkers [cytochrome b-245 alpha 
polypeptide (CYBA) (rs4673, rs1049255), cytochrome P450 superfamily (CYP2D6) 
(rs1065852), and interleukin 6 receptor (IL6R) (rs2228145).  
Although these findings are promising, identifying specific genetic variants that 
associate with the BP response to AE remains a significant challenge. Specifically, BP 
candidate gene studies are limited by small sample sizes, a small number of common 
single nucleotide polymorphisms (SNPs) examined, and lack of statistical correction for 
multiple comparison testing. For these reasons, BP candidate gene association studies are 
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plagued by a lack of replication, and ultimately, a large proportion of the variability in the 
BP response to AE as related to genotype is left unexplained.   
Meta-analysis systematically and quantitatively integrates the results of a body of 
literature addressing a related hypothesis, ultimately increasing the sample size and 
power to detect statistical differences (Bornstein, 2009). In addition, meta-analysis is able 
to identify sources of diversity across different study designs and detect biases and 
deficiencies in research (Ioannidis & Lau, 1999). Theoretically, meta-analysis should be 
able to address some of the limitations of candidate gene association studies by 
increasing the sample size to detect genotype/phenotype associations with the BP 
response to AE.  
 In summary, 26 different candidate gene polymorphisms have been reported to be 
associated with the BP response to AE. However, identifying specific genetic variants 
accounting for the BP response variability remains a significant challenge due to the 
limitations in candidate gene association studies examining the BP response to AE. 
Theoretically, the use of meta-analysis should be able to increase the sample size of 
current BP candidate gene studies to detect genotype/phenotype associations and provide 
clearer insights regarding the role of genetic predispositions on the BP response to AE. 
This study serves as the first meta- analysis to systematically and quantitatively integrate 
the results of candidate gene association studies and the BP response to AE. In addition, 
this study attempted to identify the specific genetic variants (if any) that associate with 





Specific Aims & Hypotheses 
The primary aim of this study was to perform a meta-analysis of candidate gene 
association studies examining the BP response to AE. Through application of 
meta-analytic procedures, this study intended to identify the overall and individual 
genotype effect size values accounting for the variability in the BP response to AE.  
Specific Aim 1: To determine the overall and individual genotype effect size values that 
account for the missing BP response variability in AE. 
Hypothesis 1: The overall and individual genotype effect size values on the BP response 
to AE will be small to medium across studies.   
Specific Aim 2: To disaggregate candidate gene polymorphisms based upon the number 
of minor alleles (i.e., 0, 1, or 2) and to determine both the overall and individual additive 
effect of candidate genes on the BP response to AE.  
Hypothesis 2: As the number of minor alleles increase, the magnitude of the BP reduction 
resulting from AE will be greater.   
Specific Aim 3: To investigate the pairwise interactive effects of genotype  
(i.e., 0 vs. 1, 0 vs. 2, and 1 vs. 2 minor alleles) within candidate gene polymorphisms and 
the BP response to AE.  
Hypothesis 3: Genotype groups with the greater number of minor alleles will reduce BP 
in response to AE more than will genotype groups with the greater number of common 
alleles.  
Specific Aim 4: To examine the moderating effects of study level sample features  
 (i.e., age, gender, BMI, pre-exercise BP) on the BP response to AE. 
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Hypothesis 4: Candidate gene polymorphisms will better predict the unexplained 
variability in the BP response to AE than will study level sample features. 
METHODS 
This chapter outlines the methods used to perform this meta-analysis. In 
particular, this chapter first discusses the literature search strategy that was used to gather 
relevant studies for this meta-analysis. Then, the predetermined inclusion/exclusion 
criteria, study outcome measure(s), and specific meta-analytic and statistical procedures 
used to perform this meta-analysis will be discussed.  
Literature Search 
Search methods for identifying relevant studies   
A systematic search was conducted using the following electronic databases: 
MEDLINE (to April 2013), Biosis (to April 2013), Scopus (to April 2013), and Web of 
Science (to April 2013). The keywords “blood pressure,” “exercise,” “randomized 
control trial,” and “genes” were used in combination with medical subject heading 
(MeSH) descriptors to search the databases for relevant studies [Table 3, Appendix B]. 
Article citation lists were also reviewed to identify additional studies. No language 
restrictions were applied when attempting to locate studies for inclusion in this 
meta-analysis.  
The studies produced from the systematic search were screened via title and 
abstract by two coders (MLB, KAL) for inclusion/exclusion criteria. To confirm the 
accuracy of the screening process, the coders re-screened all studies that were initially 
excluded to check for subtle errors (e.g., identifying excluded studies meeting the 
predetermined inclusion criteria). Studies were included if they: 1) involved an acute 
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(response to a single bout of exercise) or chronic (response to training) AE intervention; 
2) measured pre- and post-AE BP by genotype; 3) examined at least one candidate gene 
polymorphism for association with the BP response to AE; and 4) contained a 
case-control, cross-sectional, or family based study design. Studies were excluded if they: 
1) involved animal or non-human models; 2) included literature lacking a peer review 
process; or 3) examined the BP response to AE without a candidate gene polymorphism 
such as in heritability or linkage studies [Appendix C]. 
Table 3. Keywords used in the literature search. 
Blood Pressure-Keywords Genetic-Keywords Exercise-Keywords 
Mean Arterial Gene(s) Exercise(s) 
Blood Pressure(s) Genotype(s) Running 
Arterial Pressure(s) Single Nucleotide Polymorphism(s) Cycle(s) 
Hypertension Polymorphism Cycling 
Hypotension Deoxyribonucleic Acid Walking 
Normotension Minor Allele(s) Treadmill 
Hypertensive Genetic Endurance Training 
Hypotensive  Weight Training 
Normotensive  Speed Training 
Systolic Pressure  Training Duration 
Diastolic Pressure  Training Frequency 
Pulse Pressure  Training Intensity 
Venous Pressure  Aerobic Endurance 
Pressure Monitor   
Pre-Hypertension   
Blood Pressure Response   
Blood Pressure Decrease   
Blood Pressure Reduction   
Blood Pressure Monitor(s)   
Blood Pressure Measurement   
All words used in: title, original title, substance word, subject heading word, and abstract. Randomized control trial (RCT) filter 
applied in all search commands 
 
Types of participants 
 Study participants involved adults’ ≥19 years. The participants were of any 
gender, ethnicity, body composition, BP classification, or physical activity status. In 
addition, the included participants may have had a family history of heart disease or 
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HTN, possessed a known disease or chronic condition(s) related to CVD (e.g., congestive 
heart failure, metabolic syndrome [MetS]), or consumed prescribed BP medication of any 
kind. Excluded participants possessed known disease or chronic health conditions 
unrelated to CVD (e.g., cancer, neoplasms, fibromyalgia, Alzheimer’s, pregnancy, 
epilepsy, pneumonia, septicemia, HIV, AIDS, and meningitis). In addition, study 
participants consuming prescribed BP medications that did not undergo a sufficient 
washout period prior to exercise were excluded. All coded descriptive participant 
variables are listed within the comprehensive coding form [Appendix D].  
Types of interventions  
Only acute and chronic AE interventions were included in the meta-analysis. 
Acute studies must have compared an exercise intervention group to either a non-exercise 
control group or a control session. Chronic studies must have compared an exercise 
intervention group to either a non-exercise control group or control session (if possible), 
or compared an exercise intervention group cross-sectionally by genotype(s). The 
exercise interventions were permitted to occur in any setting—hospital, clinic, academic 
research laboratory, fitness center, or other venue. Exercise interventions were delivered 
via one-to-one (e.g., personal training) or in groups, and were supervised or 
unsupervised. All descriptive intervention variables that were coded are listed within the 
comprehensive coding form [Appendix D]. 
Outcome measure 
The primary goal of this meta-analysis was to determine the overall and 
individual genotype effect size values accounting for the variability in the BP response to 
AE. The overall effect size estimate was measured using Becker’s d to quantify the 
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magnitude of BP change (across all polymorphisms) in response to exercise. Becker’s d 
was computed as the post- vs. pre-exercise BP response divided by the pre-exercise 
standard deviation. The effect size estimates were then disaggregated by genotype for 
each polymorphism examined, yielding either two (dominant or recessive models) or 
three (co-dominant or additive models) d values for each study (Becker, 1988). Negative 
values of d implied BP was lower at post- versus pre-exercise, thereby demonstrating a 
favorable response to exercise. 
Data extraction  
 After screening potential articles for inclusion/exclusion criteria via title and 
abstract, the remaining studies underwent a full-text review. Studies that continued to 
fulfill the inclusion/exclusion criteria were subject to data extraction via a 246-item 
coding form [Appendix D]. Two coders (MLB, KAL) independently performed the data 
extraction procedures; the coders were trained from an expert in meta-analysis (TBH-M) 
with 10 pilot studies to ensure accurate and reliable interpretation of coded studies. The 
coders then reviewed the 10 pilot studies with the meta-analytic expert and resolved 
discrepancies in coding. If a consensus could not be reached, a third coder mediated 
unresolved discrepancies. Once an inter-rater reliability of 0.80 was reached on the 
sampled pilot studies, the coders then coded the remaining included studies. The coders 
continued to meet weekly to review the coded studies and compare coded data 
line-by-line, continuing to address any questions, concerns or issues encountered 
throughout the data extraction process. Extracted study and subject data included 
variables related to: age, body mass index (BMI), baseline or pre-exercise systolic (SBP) 
and diastolic (DBP) BP, gender, ethnicity, study quality, and geographical region or 
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population. Extensive and detailed study, subject, and intervention variables were coded 
on the comprehensive coding form [Appendix D]. 
Study Quality  
 Study quality was assessed with the Down and Black’s (1998) methodological 
quality checklist, a 27-item questionnaire with items in the five general domains of: 1) 
the appropriateness of assessing randomized and non-randomized control trials; 2) the 
provision of computing both an overall score for study quality and a profile of scores not 
only for the quality of reporting; 3) internal validity (bias and confounding); 4) external 
validity; and 5) power [Appendix D].  
Data extraction agreement  
 A Kappa statistic was computed to assess inter-coder reliability for categorical 
variables. The Kappa statistic is interpreted as follows: < 0.00 = poor, 0.00-0.20 = slight, 
0.21-0.40 = fair, 0.41-0.60 = moderate, 0.61-0.80 = substantial and 0.81-1.00 = almost 
perfect agreement between coders (Meyer, 1999). The Pearson’s r correlation is a 
statistical measure that ranges in value from +1 and -1, and accounts for the percent of 
between rater agreements for a given variable. The Pearson r correlation is interpreted as 
follows: ≤ -0.70 = very strong negative relationship, -0.40 to -0.69 = strong negative 
relationship, -0.30 to -0.39 = moderate negative relationship, -0.20 to -0.29 = weak 
negative relationship, -0.01 to -0.19 = no or negligible relationship, +0.01 to +0.19 = no 
or negligible relationship, +0.20 to +0.29 = weak positive relationship, +0.30 to +0.39 = 
moderate positive relationship, +0.40 to +0.69 = strong positive relationship, ≥ +0.70 = 
very strong positive agreement. Reliability was assessed regularly during the coding of 
studies (every 2 weeks) to ensure that inter-coder agreement remained at high levels.  
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Effect Size Estimate   
The overall effect size estimate was computed using Becker’s d to quantify the 
magnitude of BP change (across all polymorphisms) in response to exercise. Becker’s d 
was computed as the post- vs. pre-exercise BP response divided by the pre-exercise 
standard deviation (Becker, 1998). The effect size estimates were then disaggregated by 
genotype for each polymorphism examined. The purpose of this procedure was to 
quantify the individual effect size estimate of each genotype for every polymorphism 
examined for every intervention arm of each study. Therefore, there were either two 
(dominant or recessive models) or three (co-dominant or additive models) d values for 
each study intervention (Becker, 1988). Acute studies were computed as the post- vs. 
pre-exercise BP response compared to control while chronic studies were computed with 
no control comparison. Negative values of d implied BP was lower at post- versus 
pre-exercise, implying a favorable response to exercise.  
Average Effect Size Calculation (Fixed Effects vs. Random Effects) 
Fixed Effects Modeling  
 Analyses followed fixed-effects assumptions because studies meeting our 
predetermined inclusion/exclusion criteria were of small quantity and therefore offered 
low precision in estimating population variation in effects. Fixed-effects models assume 
that all studies in a meta-analysis share a common effect size (Borenstein, 2009). Each 
effect size value was assigned a weight that corresponded to the inverse study variance.  
Random Effects Modeling  
 Random effects modeling, like fixed effects modeling, is weighted by the inverse 
study variance. However, random effects modeling also factors between-study variance 
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into the estimate of the constant, denoted as τ2 (tau-squared). The random-effects model 
assumes that there are uncontrolled factors influencing the effect sizes of the studies’ 
observed. Under heterogeneity, such models provide wider confidence intervals around 
mean effect sizes, reflecting a relatively conservative analytic approach (Bornstein, 
2009). However, because the number of studies meeting our predetermined 
inclusion/exclusion criteria was small, the random effects model was not used in the 
meta-analysis (Bornstein, 2009).  
Publication Bias  
 Potential for publication bias was assessed graphically via forest plots and funnel 
plots, and statistically via Begg’s and Egger’s methods (Beggs & Mazumder, 1994; 
Borenstein, 2009; Egger, Davey Smith, Scneider, & Minder, 1997). Tests for publication 
bias assume that asymmetries in the distribution of effect size estimates imply publication 
biases. As a result, forest plots illustrate the variability of an effect size between sampled 
studies, while funnel plots depict an effect size across sampled studies by plotting an 
effect size against its variance (Borenstein, 2009). The graphical presence of publication 
bias was identified as an asymmetrical funnel shape in a funnel plot, while symmetrical 
funnel shapes indicated the absence of publication bias (Borenstein, 2009). If publication 
bias was present in the meta-analysis, the “Trim and Fill” method was used (Duval & 
Tweedie, 2000). The “Trim and Fill” method provides a statistically unbiased pooled 
estimate of study effects with varying results by imputing the presence of missing studies 






 The Q (unstandardized) and I2 (standardized)statistics were used to determine if 
the between-study variance exceeded what would be expected on the basis of sampling 
error alone, justifying an inference of heterogeneity (Higgins & Thompson, 2002; 
Huedo-Medina, Sanchez-Meca, Marin-Martinez, & Botella, 2006). The Q statistic is an 
unstandardized inference of homogeneity, making it difficult to interpret in meta-analysis 
(Higgins & Thompson, 2002). Therefore, the I2 statistic was indexed on the basis of Q to 
assess homogeneity (Huedo-Medina et al., 2006). I2 values range from 0-100%, with 
values closer to 0% indicating homogeneity (studies exhibit a similar or homogenous 
pattern) and values closer to 100% indicating heterogeneity (studies exhibit a dissimilar 
or heterogeneous pattern) between study effect sizes (Huedo-Medina et al., 2006).   
Meta-Regression  
 Moderator (i.e., covariate) analyses were examined using bivariate and 
multivariate meta-regression techniques to determine their influence on the BP response 
to AE. Analyses first controlled for clinical sample characteristics (i.e., age, BMI, gender, 
and pre-exercise BP) and then examined whether genotype BP associations explain the 
unique variation in ds. Candidate gene meta-regression analyses followed an additive 
model to determine the linear trends of genotype by the number of minor alleles in a 
given polymorphism. When there were at least nine effect size observances (cases) for a 
given candidate gene polymorphism, meta-regressions were also used to compare each 
pair of possible genotype combinations (i.e., 0 vs. 1, 0 vs. 2, and 1 vs. 2 minor alleles). If 
a significant genotype BP association appeared on a bivariate basis for a particular 
polymorphism, the polymorphism was then evaluated against the entire set of ds in the 
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multivariate model. Specifically, an interaction term was computed to determine whether 
the associated polymorphism differed significantly from all other polymorphisms in the 
model. The moving constant technique was used to estimate d for different genotypes that 
meta-regression models linked to the BP response to AE (Johnson & Huedo-Medina, 
2011). The moving constant technique illuminates patterns in multivariate regression 
models by estimating both effect size values and confidence intervals at moderator levels 
of interest and the meta-regression line itself (Johnson & Huedo-Medina, 2011). To 
control for simultaneous statistical tests, a Bonferroni-corrected α-level of p ≤. 03 (k=44) 
was used for dominant/recessive models with two genotype groupings and p ≤.02 
(k=286) was used for co-dominant/additive models with three genotype groupings (Abdi 
& Valentin, 2007).   
Statistical Computing 
 Analyses were completed using Stata version 11.1 with macros (i.e., meanes, 
metareg, metaf, metan, metabias, and confunnel) for meta-analysis (StataCorp, 2009; 
Lipsey & Wilson, 2001; Wilson, 2001; Harris et al., 2008; Sterne, Harris, Harbord, 
Steichen, 2009). Data extraction agreement was completed using the Statistical Package 
for the Social Sciences and a Microsoft Excel Kappa statistic calculator (SPSS Inc., 2005; 
Huedo-Medina & Johnson, 2011). Individual effect size estimates were completed with a 
Microsoft Excel calculator (Huedo-Medina & Johnson, 2011).  
Limitations 
Meta-analysis synthesizes prior empirical evidence and is therefore subject to the 
limitations of the literature it examines. Individual study quality of included trials can 
significantly impact the quality of the meta-analysis. To control for individual study 
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quality, a rigorous inclusion/exclusion criteria was used to screen relevant studies, and 
individual study quality was assessed with the Downs and Black methodological quality 
checklist (Downs & Black, 1998). In addition, study quality was examined as a 
moderating variable in meta-regression analyses to determine whether higher quality 
studies yield differing results from lower quality studies.  
 Secondly, because we examined published articles, our findings may have been 
subject to publication bias (Bornstein, 2009). We searched multiple databases and used 
broad search terminology when attempting to locate as many possible articles relating to 
the meta-analysis. However, there is the possibility that some studies were not located, 
perhaps skewing our effect size results. Therefore, publication bias was assessed 
graphically with funnel and forest plots, as well as with statistical procedures (i.e., Begg 
& Egger tests) to correct for publication bias when present (Borenstein, 2009).  
 Lastly, data extraction may also be a source of limitation. Despite training, a 
comprehensive coding form, and performing multiple pilot tests, subtle errors were still 
possible when coding large amounts of literature. To limit coding error, we used two 
coders. Coders were trained from an expert in meta-analysis (TBH-M) with 10 pilot 
studies. If discrepancies in coding could not be resolved, a third coder was used to 
mediate. Once an inter-rater reliability of 0.80 was reached on the 10 sampled pilot 
studies, coders began coding. Coders met weekly to review all coded studies, comparing 
answers line-by-line, and addressing any questions, concerns, or issues encountered 
throughout the data extraction process. In addition, data extraction agreement was 





 The primary goal of this meta-analysis was to identify the most relevant candidate 
genes associated with the BP response to AE. This study did not intend to affirm 
causation among candidate genes and the BP response to AE; rather, it aimed to elucidate 
which genetic variants may be associated to the BP response to AE. In addition, this 
meta-analysis attempted to circumvent the limitations of candidate gene association 
studies examining the response of health/fitness phenotypes to exercise by increasing the 
sample size needed to detect genotype and health/fitness phenotype associations. The 
information gained from this meta-analysis provides insight to exercise scientists 
examining the response variability of health/fitness phenotypes to exercise by 
determining the emergence of promising candidate gene polymorphisms that should be 
explored in future research.  
Clinical Significance & Application 
The findings of our meta-analysis provide exercise scientists with new 
information on the role genetic predispositions might pose on the BP response to AE. 
New knowledge gained from this study may be useful in refining the Ex Rx for HTN by 
identifying candidate genes that may and may not influence the BP response to AE. This 
information can also be used to better tailor individualized Ex Rx for those who do and
 
do not respond to AE as a therapeutic modality to prevent, treat, and control HTN. In 
addition, a better understanding of how genetic predispositions modulate the 
antihypertensive effects of AE may provide biological insight into the regulatory 





Aerobic Exercise Training  
Study Characteristics 
There were 523 potentially relevant studies retrieved. Of these, 11 (N=2,646) 
studies met the predetermined inclusion/exclusion criteria and examined ten candidate 
gene polymorphisms (Feairheller et al., 2009; Flavell et al., 2006; Hautala et al., 2006; 
Jones et al., 2006; Rankinen et al., 2000; Rankinen et al., 2002; Rauramaa et al., 2002; 
Rivera et al., 2001; Takakura et al., 2002; Vargas et al., 2013; Zhang et al., 2002)  
[Figure 1]. The ten candidate gene polymorphisms examined were: angiotensin 
converting enzyme (ACE) (rs4340) (k=3), angiotensinogen (AGT) (rs699) (k=4), 
cholinergic receptor (CHRM2) (rs324640, rs8191992) (k=1), cytochrome b-245 alpha 
polypeptide (CYBA) (rs4673, rs1049255) (k=1), guanine nucleotide binding protein, beta 
polypeptide 3 (GNB3) (rs5443) (k=1), interleukin 6 receptor  (IL6R) (rs2228145) (k=1), 
lipoprotein lipase (LPL) (rs328) (k=1), and transforming growth factor, beta 1 (TGFB1) 
(rs1800470) (k=1).  
In total, 59 effect size estimates were computed for SBP and DBP, yielding 118 
effect size estimates. Studies were completed in the US (45%), UK (27%), Japan (18%), 
and South America (9%) with the exercise interventions completed in academic research 
laboratories (82%) and/or university hospitals (18%). The average study quality score 
was 15.2±2.1 out of a possible 26 points on the Downs and Black (1998) scale, indicating 





Study Characteristics  
Subjects were mostly middle aged (44.2±10.7 yr), overweight (26.9±2.6 kg⋅m-2) 
non-Hispanic white (N=1,764) men (N=1,288) and women (N=1,358) with pre-HTN 
(134.4±11.9/78.6±9.3 mmHg).   
Aerobic Exercise Intervention Characteristics 
Aerobic exercise (AE) interventions were performed at an average vigorous 
intensity of 62.3±7.5% VO2max for 43.8±11.6 min⋅session-1, 3.6±1.2 d⋅wk-1 for 15.3±7.6 
wk. AE modalities included stationary cycling (k=6), walking (k=3), and two not 
specified. Participants were supervised by a trained exercise professional in seven AE 
interventions, unsupervised in two, and not reported in two. Exercise adherence was 
reported in only three of the AE interventions, with a mean adherence rate of 87.6±1.1%. 
The BP Response to Aerobic Exercise Training 
The weighted mean effect size (d+) for the change in BP after versus before AE  
training was small but statistically significant (SBP d+= -0.21 [95% CI= -0.247, -0.168], 
-3.1 mmHg, I2=77.8%; and DBP d+= -0.20 [95% CI= -0.235, -0.158], -1.9 mmHg, 
I2=62.2%).  
Multi-Predictor Analyses 
Sample Features Associated with the BP Response to Aerobic Exercise Training 
Sample features explained a large portion of the variance in the BP response to 
AE training, 71.5% for SBP (Multiple R=0.845, P<0.001) and 59.1% for DBP (Multiple 
R=0.769, P<0.001) [Tables 4 & 5]. Reductions in SBP after versus before AE training 
were greater in samples with higher resting SBP (β=-0.68, P<0.001); that were younger 
(β=0.34, P<0.01); and that included more women than men (β=0.41, P<0.001). For, SBP 
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decreased 8.8 mmHg among those with HTN, d+= -0.56 [95% CI= -0.644, -0.469], and 
3.0 mmHg among those with Pre-HTN, d+= -0.20 [95% CI= -0.250, -0.158], while SBP 
increased 2.5 mmHg among those with normal BP, d+=0.13 [95% CI=0.044, 0.211]. SBP 
decreased 8.8 mmHg among young adults, d+= -0.50 [95% CI= -0.625, -0.374], and 3.1 
mmHg among middle-aged adults, d+= -0.22 [95% CI= -0.262, -0.169], while SBP 
increased 0.3 mmHg among older adults, d+= -0.04 [95% CI= -0.156, 0.074]. Lastly, 
SBP decreased 8.4 mmHg among samples containing women only, d+= -0.55 [95% CI= 
-0.669, -0.422], and 3.0 mmHg among samples containing approximately equal numbers 
of women and men, d+= -0.20 [95% CI= -0.250, -0.156], while SBP increased 2.6 mmHg 
among samples containing men only, d+=0.15 [95% CI= 0.012, 0.282]. 
Reductions in DBP after versus before training were greater in samples with 
higher resting DBP (β= -0.56, P=0.01); and that included more women than men (β=0.52, 
P<0.001). For, DBP decreased 5.3 mmHg among those with HTN, d+= -0.49 [95% CI= 
-0.651, -0.332], and 2.3 mmHg among those with Pre-HTN, d+= -0.23 [95% CI= -0.276, 
-0.183], while DBP increased 0.5 mmHg among those with normal BP, d+=0.01 [95% 
CI= -0.120, 0.131]. DBP decreased 5.4 mmHg among samples containing women only, 
d+= -0.55 [95% CI= -0.660, -0.436], and 2.2 mmHg among samples containing 
approximately equal numbers of women and men, d+= -0.22 [95% CI= -0.269, -0.175], 
while DBP increased 1.0 mmHg among samples containing men only, d+=0.10 [95% CI= 






Candidate Gene Associations with the BP Response to Aerobic Exercise Training 
 AGT M235T (rs699) significantly associated with the DBP response to AE 
training in the additive model of genotype association (Multiple R=0.058, P=0.02) 
[Table 4]. Specifically, the reduction in DBP was greater among individuals with the 
AGT MM genotype (N= 174) (d+= -0.53 [95% CI= -0.684, -0.374], -5.6 mmHg) 
compared to those with the AGT TT genotype (N=179) (d+= -0.23 [95% CI= -0.389, 
-0.064], -2.7 mmHg) after versus before AE training [Table 5]. No parallel effects were 
found with the AGT M235T polymorphism and the SBP response to AE training 
(P=0.82). In addition, none of the nine other candidate polymorphisms significantly 
associated with either the SBP or DBP response to AE training (P>0.05). 
Acute Aerobic Exercise 
Study Characteristics 
There were 523 potentially relevant studies retrieved. Of these, four studies met 
the predetermined inclusion/exclusion criteria and examined six candidate gene 
polymorphisms (Augeri et al., 2009; Blanchard et al., 2006; Pescatello et al., 2007a, 
2009) [Figure 2]. The six candidate gene polymorphisms that were examined were: 
angiotensin converting enzyme (ACE) (rs4340) (k=1), adducin 1 (alpha) (ADD1) (rs4961) 
(k=1), angiotensin 2 type I receptor (AGTR1) (rs5186) (k=1), aldosterone synthase 
(CYP11B2) (rs1799998) (k=1), guanine nucleotide binding protein system alpha subunit 
(GNAS) (rs7121) (k=1), and endothelial nitric oxide synthase (NOS3) (rs2070744) (k=1). 
In total, 128 effect size estimates were computed; 32 for SBP and DBP versus control to 
total 64 effect size estimates, plus 32 for the two experimental conditions to total 64 
effect size estimates. All interventions were conducted in the US and in one laboratory. 
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The average study quality score was 18.2±2.4 out of a possible 26 points on the Downs 
and Black (1998) scale, indicating moderate to good study quality.  
Study Participants 
Subjects were middle aged (44.1±1.0 yr), overweight (29.9±0.3 kg⋅m-2) 
non-Hispanic white (N=50) men with HTN (145.7±1.7/85.8±0.9 mmHg).   
Aerobic Exercise Intervention Characteristics 
The aerobic exercise (AE) intervention involved acute cycle exercise performed at 
light (40% VO2peak) and moderate (60% VO2peak) intensity for 40 min⋅session-1. All 
participants were supervised by a trained exercise professional and were adherent to the 
AE intervention.   
The BP Response to Acute Aerobic Exercise  
The weighted mean effect size (d+) for the change in BP after versus before acute 
AE compared to control was large for SBP (d+= -0.62 [95% CI= -0.745, -0.504], -5.5 
mmHg, I2=48%), and small for DBP (d+= -0.28 [95% CI= -0.398, -0.162], -1.7 mmHg, 
I2=0%).  
Multi-Predictor Analyses 
Sample Features Associated with the BP Response to Acute Aerobic Exercise  
Sample features explained a large portion of the variance in the BP response to 
acute AE for SBP (Multiple R=0.907, P<0.001), accounting for 82.3% of the variability 
in the SBP response. Sample features explained 55.2% of the DBP response to acute AE 
(Multiple R=0.743, P=0.12); however, this correlation did not achieve statistical 
significance [Table 6]. Univariate analyses were unable to determine which sample 
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feature(s) explained most of the variability in the SBP response to acute AE because all 
studies involved participants from the same sample. 
Candidate Gene Associations with the BP Response to Acute Aerobic Exercise  
 Beyond the influence of sample features, candidate genes explained 4.6% of the 
variance in the SBP response to acute AE (Multiple R=0.214, P=0.08), a trend 
approaching significance. Similarly, candidate genes explained 6.0% of the variance in 
the DBP response to acute AE (Multiple R=0.245, P=0.08), a trend approaching 
significance. The analyses of individual polymorphisms were not feasible due to the low 
number of interventions and observations, and because all studies were derived from a 
single trial, making non-independence a potential threat.
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Table 4. Blood pressure response to aerobic exercise training attributable to sample features 
and candidate genes, where the linear trends of candidate gene minor alleles comprised a test 
of the additive model of gene association. 
 
Sample features’ association 
with BP response to AEa  
Candidate gene association 
with BP response to AEb 
Candidate gene(s) k Multiple R p  k Multiple R ∆ pc 
SBP 
All  59 0.845 <0.001†  59 0.120 0.22 
        
ACE 15 0.790 0.08  15 0.396 0.64 
AGT 15 0.926 <0.001†  15 0.116 0.82 
DBP 
All  59 0.769 <0.001†  59 0.108 0.20 
        
ACE 15 0.759 0.10  15 0.159 0.07 
AGT 15 0.890 <0.001†  15 0.058  0.02† 
Note 1. Models in each row are somewhat independent of the models in the other rows. 
Note 2. Univariate sample feature analyses do not appear in this table since the focus of the analysis was on candidate gene polymorphisms. 
Note 3. The term All under candidate gene(s) is the aggregate model of all nine candidate gene polymorphisms examined in this meta-analysis. 
Abbreviations. AE=aerobic exercise. BP=blood pressure. ∆=change. DBP=diastolic blood pressure. †=statistically significant association. 
RAS=renin angiotensin system. SBP=systolic blood pressure. Gene abbreviations. ACE= angiotensin converting enzyme. 
AGT=angiotensinogen. 
aCompeting variables are mean sample age, proportion male, mean BMI, and mean SBP prior to exercise. 
bThese models control for the competing variables, where possible. 
cBonferroni adjusted p-value set at p≤.02. 
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Table 5. Blood pressure response to aerobic exercise training attributable to sample features and 
candidate genes, where pair-wise comparisons of genotype were made. 
 
Sample features’ association 
with BP response to AEa 
 Candidate gene association 
with BP response to AEb 
Candidate gene(s) k Multiple R p  k Multiple R ∆ pd 
SBP 
All trials        
CC  vs. MM 37 0.835 <0.001†  37 0.175 0.41 
CM vs. MM 38 0.837 <0.001†  38 0.159 0.28 
CC  vs. CM 37 0.848 <0.001†  37 0.001 0.60 
Gene-specific comparisons for studies with independent replicationsc 
AGT        
MM vs. TT 10 0.863 <0.001†  10 0.211 0.38 
MT vs. TT 11 0.958 <0.001†  11 0.232 0.76 
MM vs. MT 9 0.976 <0.001†  9 0.111 0.91 
DBP 
All trials        
CC  vs. MM 37 0.569 <0.001†  37 0.153 0.81 
CM vs. MM 38 0.572 <0.001†  38 0.128 0.95 
CC  vs. CM 37 0.682 <0.001†  37 0.001 0.46 
Gene-specific comparisons for studies with independent replicationsc 
AGT        
MM vs. TT 10 0.822 <0.01†  10 0.076    0.02† 
MT vs. TT 11 0.929 <0.001†  11 0.093 0.05 
MM vs. MT 9 0.949 <0.001†  9 0.221 0.32 
Note 1. Models in each row are somewhat independent of the models in the other rows.  
Note 2. Univariate sample feature analyses do not appear in this table since the focus of the analysis was on candidate gene polymorphisms. 
Note 3. The term All trials under candidate gene(s) refers to the pair-wise aggregate models of all nine candidate gene polymorphisms examined in 
this meta-analysis.  
Abbreviations. AE=aerobic exercise. BP=blood pressure. ∆=change. DBP=diastolic blood pressure. †=statistically significant association. 
RAS=renin angiotensin system. SBP=systolic blood pressure. Gene abbreviations. ACE=angiotensin converting enzyme. AGT=angiotensinogen.  
aCompeting variables are mean sample age, proportion male, mean BMI, and mean SBP prior to exercise.  
bThese models control for the competing variables, where possible.   





Table 6. Ambulatory blood pressure response to acute aerobic exercise compared to control, attributable to 
sample features and candidate genes.  
Blood Pressure 
Sample characteristics association 
with BP response to AEa 
 
Candidate gene association 
with BP response to AEb 
k Multiple R p k Multiple R ∆ pc 
 
SBP 24 0.907  <0.001†  24 0.214 0.08 
 























Note 1. Models in each row are somewhat independent of the models in the other rows.  
Note 2. Univariate sample feature analyses do not appear in this table since the focus of the analysis was on candidate gene polymorphisms. 
Note 3. All six-candidate gene polymorphisms are shown in aggregate form since there were not enough degrees of freedom to perform individual polymorphism analyses. 
Abbreviations. AE=aerobic exercise. BP=blood pressure. ∆=change. DBP=diastolic blood pressure. †=statistically significant association. SBP=systolic blood pressure. 
aVariables included: mean sample age, proportion male, BMI, and BP prior to exercise.  
bThese models control for the competing variables, where possible.  



















Potentially relevant trials 
(k=523) 
Retrieved trials (k=120) 
Potentially appropriate 
trials (k=80) 
Trials included in final 
analysis (k=11) 
Trials excluded (k=403) 
1. No use of exercise 
2. No use of genetics 
3. No examination of BP 
4. Targeted animal/non-human models 
5. Non-peer reviewed publication 
 
Trials excluded (k=40) 
1. Twin studies without examination of a candidate gene 
2. Heritability studies without examination of a candidate gene 
3. Family-based studies without examination of a candidate gene 
 
Trials excluded (k=69) 
1. No AE intervention 
2. No pre/post BP measurement by genotype 
3. No candidate gene polymorphism examined 
 
Effect sizes calculated in final analysis (k=118) 
1. SBP (k=59) 


















Potentially relevant trials 
(k=523) 
Retrieved trials (k=120) 
Potentially appropriate 
trials (k=80) 
Trials included in final 
analysis (k=4) 
Trials excluded (k=403) 
1. No use of exercise 
2. No use of genetics 
3. No examination of BP 
4. Targeted animal/non-human models 
5. Non-peer reviewed publication 
 
Trials excluded (k=40) 
1. Twin studies without examination of a candidate gene 
2. Heritability studies without examination of a candidate gene 
3. Family-based studies without examination of a candidate gene 
 
Trials excluded (k=76) 
1. No AE intervention 
2. No pre/post BP measurement by genotype 
3. No candidate gene polymorphism examined 
4. No control group/session included 
 
Effect sizes calculated in final analysis (k=128) 
1. SBP 40% VO2peak (k=32) 
2. DBP 40% VO2peak (k=32) 
3. SBP 60% VO2peak (k=32) 





The purpose of this meta-analysis was to examine the effects of candidate gene 
polymorphisms on the BP response to aerobic exercise (AE). We also investigated patient 
characteristics that influenced the BP response to AE. The major findings of this 
meta-analysis were clinical sample features, rather than candidate gene polymorphisms, 
explained most of the variability in the BP response to AE. Collectively, age (SBP 0.6%; 
DBP 3.0%), gender (SBP 30.6%; DBP 23.1%) and resting BP (SBP 51.2%; DBP 8.1%) 
accounted for 82.4% of the SBP and 34.2% of the DBP response to AE training. 
Subgroup analyses of these sample features showed BP reductions were greater in 
samples that were younger, that included more women than men, and that had a higher 
pre-exercise resting BP. SBP was reduced 5.7 mmHg and 9.1 mmHg more among 
younger than middle-aged and older adults, respectively. SBP and DBP were reduced 
5.4/3.2 mmHg and 11.0/6.4 mmHg more among women than gender mixed samples and 
samples with men only, respectively. Finally, SBP and DBP were reduced 5.8/3.0 mmHg 
and 11.3/5.8 mmHg more among persons with HTN than persons with prehypertension 
(pre-HTN) and normal BP, respectively.  
In contrast to the significant proportion of variance in the BP response to AE 
explained by clinical sample features, the overall contribution of candidate gene 
polymorphisms on the BP response to AE training was small and non-significant. In fact, 
only the AGT M235T single nucleotide polymorphism showed a significant association 
with the DBP response to AE training, yet we found it to explain only 0.3% of the 
variability in the DBP response. Pairwise comparisons of AGT M235T genotypes 
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revealed those with the MM genotype reduced DBP 2.9 mmHg more in response to AE 
training compared to those with the AGT TT genotype.  
Similar to AE training, the overall contribution of clinical sample features on the 
BP response to acute AE was large and significant, explaining 55.2% to 82.3% of the 
variability. In contrast, the contribution of candidate gene polymorphisms was marginally 
significant (P=0.08), but did account for 21.4% to 24.5% of the BP response to acute AE. 
The contribution of individual polymorphisms on the BP response to acute AE could not 
be determined due to the small number of interventions and observations, and because all 
studies were derived from a single trial. In summary, our meta-analytic findings showed 
that clinical sample features explained a meaningful proportion of variance in the BP 
response to AE, ranging from 59.1% to 71.5% in response to AE training and 55.2% to 
82.3% in response to acute AE, while the contribution of candidate gene polymorphisms 
modulating the BP response to AE was small and non-significant.   
To date (to March 2013), 26 polymorphisms have been reported to be associated 
with the BP response to acute and chronic AE (Augeri et al, 2009; Blanchard et al., 2006; 
Delmonico et al., 2005; de Luis et al., 2006; Feairheller et al., 2009; Flavell et al., 2006; 
Franks et al., 2004; Grove et al., 2007; Hagberg et al., 1999; Hautala et al., 2006; Jones et 
al., 2006; Kilpelainen et al., 2008; Pescatello et al., 2007a; Pescatello et al., 2007b; 
Pescatello et al., 2009; Rankinen et al., 2000; Rankinen et al., 2002; Rankinen et al. 2007; 
Rauramaa et al., 2002; Rivera et al., 2001; Takakura et al., 2006; Vargas et al., 2013; 
Zateyschikov et al., 2007; Zhang et al., 2002).  Of these, 16 polymorphisms include those 
involved with: 1) Renin Angiotensin System (RAS) and/or Renal Function [angiotensin 
converting enzyme (ACE) (rs4340), adducin 1 alpha (ADD1) (rs4961), angiotensinogen 
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(AGT) (rs699), angiotensin 2 type 1 receptor (AGTR1) (rs5186), and aldosterone synthase 
(CYP11B2) (rs1799998); 2) Sympathetic Nervous System [adenosine monophosphate 
deaminase 1 (AMPD1) (rs17602729), adrenergic receptor, beta 1 (ADRB1) (rs1801253), 
adrenergic receptor, beta 2 (ADRB2) (rs1042714), cholinergic receptor (CHRM2) 
(rs324640, rs8191992), guanine nucleotide binding protein system alpha subunit (GNAS) 
(rs7121), and guanine nucleotide binding protein, beta polypeptide 3 (GNB3) (rs5443)]; 
and 3) Nitric Oxide Synthase Pathway and/or Vascular Function [endothelin 1 (EDN1) 
(rs5370, rs2070699, rs5369), endothelial nitric oxide synthase (NOS3) (rs2070744), and 
transforming growth factor, beta 1 (TGFB1) (rs1800470)]. The remaining 10 
polymorphisms are implicated in the etiology of HTN as established or emerging 
cardiovascular disease risk factors and include: 1) Dyslipidemia [apolipoprotein (APOE) 
(rs7412, rs429358), fatty acid binding protein 2 (FABP2) (rs1799883), and lipoprotein 
lipase (LPL) (rs328)]; 2) Obesity [leptin receptor (LEPR) (rs1137100)]; and 3) 
Inflammatory Biomarkers [cytochrome b-245 alpha polypeptide (CYBA) (rs4673, 
rs1049255), cytochrome P450 superfamily (CYP2D6) (rs1065852), and interleukin 6 
receptor (IL6R) (rs2228145).  
Of the 26 polymorphisms reported to be associated with the BP response to AE, 
16 met our inclusion criteria and were included in our meta-analysis. Of these, only one 
polymorphism emerged as significantly associated with the DBP response to exercise in 
our meta-analysis, AGT M235T, and explained only 0.3% of the variability. Our finding 
confirmed those of Rankinen and Rauramaa et al. in that the AGT M235T polymorphism 
was associated with the DBP response to AE training, with greater DBP reductions 
observed with the AGT MM genotype than the AGT TT genotype. (Rankinen et al., 2000; 
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Rauramaa et al., 2002). Furthermore, this single AGT M235T finding demonstrates the 
difficulty in identifying genetic variants that account for the variability in the response of 
health/fitness phenotypes to exercise like the BP response to AE.  
A proposed mechanism for the influence of the AGT M235T (rs699) 
polymorphism on the DBP response to AE training is the reported difference in plasma 
AGT levels by genotype (Rankinen et al., 2000; Rauramaa et al., 2002). Jeunemaitre et 
al. found resting plasma AGT levels were lower among M versus T allele carriers 
(Jeunemaitre et al., 1992). AGT, a substrate of renin that is released by the liver when 
blood volume is low, generates angiotensin I that is converted by ACE to angiotensin II, 
a potent vasoconstrictor. Angiotensin II increases sodium reabsorption and total 
peripheral resistance, thereby elevating BP under resting conditions. Consequently, 
Rauramaa et al. postulated higher plasma AGT concentrations among those with the AGT 
TT genotype at rest may translate to an over reactivity of the RAS during exercise, 
ultimately inducing an overproduction of angiotensin II, and a more potent constriction of 
the arterioles that counteract both the vasodilatory and antihypertensive effects of 
exercise on BP (Rankinen et al., 2000; Rauramaa et al., 2002).  
The most noteworthy finding of this meta-analysis was the clinically meaningful 
amount of BP response variability explained by clinical characteristics that included age, 
gender and resting BP, accounting for 34.2% to 82.4% of the BP response to AE training. 
Bouchard and Rankinen examined individual differences in the BP response to a 20-week 
AE training program among 481 sedentary, adult Caucasians from 98 two-generation 
families as part of the HERITAGE family study (Bouchard & Rankinen, 2000; Bouchard, 
et al., 2012). They found gender and resting SBP explained 1.6% and 32.0% of the SBP 
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response to AE training, respectively (Bouchard & Rankinen, 2000; Bouchard, et al. 
2012). Likewise, Pescatello and Kulikowich reviewed the ambulatory BP response to 
acute dynamic AE in 23 studies that primarily enrolled sedentary, overweight, 
non-Hispanic white men and women with Pre-HTN (Pescatello & Kulikowich, 2001). 
They found resting BP accounted for 27.0% to 30.0% of the ambulatory SBP and 33.0% 
to 37.0% of the ambulatory DBP response to acute AE (Pescatello & Kulikowich, 2001). 
Criqui et al. found age explained 15.0% to 44.0% of the peak SBP response to a GXT 
among 4,262 men and women in the Lipid Research Clinics Program Prevalence Study 
(Criqui et al., 1983). The findings from Bouchard and Rankinen, Pescatello and 
Kulikowich, and Criqui et al. are consistent with ours and show that the clinical sample 
features of age, gender, and resting BP explain a clinically meaningful proportion of 
variance in the BP response to AE.  
The present meta-analysis is subject to several limitations. These include the use 
of previously reported literature that contained a small number of studies. Despite our 
effort to increase the sample size by aggregating the existing literature, our sample 
remained underpowered to detect significant associations with individual polymorphisms 
occupying ≤ 9 effect size estimates. This was especially true in acute studies, which were 
derived from a single trial, making non-independence of acute analyses a threat. 
Nonetheless, recent work by Lander et al. suggests that certain epistatic interactions could 
be causing underestimations in the amount of explained heritability of complex 
phenotypes like the BP response to AE (Zuk, Hechter, Sunyaey, & Lander, 2012). Future 
research efforts should therefore move beyond analyses of individual candidate gene 
polymorphisms and examine multiple levels of gene regulation via high throughput 
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screening involving genes, their regulatory factors, and the proteins they produce to better 
explain this phenomenon of missing heritability (Ash, Eicher, & Pescatello, 2012). 
The strengths of this study lie in the meta-analytic study design. The use of 
meta-analysis allowed us to systematically integrate and quantify the results of fifteen 
candidate gene association studies, thereby enabling our ability to circumvent the 
limitations of the literature by increasing the sample size and power to detect statistical 
associations with the BP response to AE. The overall study quality of included trials was 
another strength of this meta-analysis, with mean methodological quality scores of 
18.2±2.4 and 15.2±2.1 for acute and chronic trials, respectively. This meta-analysis 
satisfied 15 of the 18 items listed on a modified version of the Assessment of Multiple 
Systematic Reviews (AMSTAR), a content-validated measurement tool used to assess the 
methodological quality of systematic reviews by addressing deficiencies in poorer quality 
reviews (Johnson et al. 2013; Shea et al., 2007) [Appendix E]. In addition to satisfying 
the items of AMSTAR, this meta-analysis also provided detailed descriptions of each 
study’s geographical location, study population (i.e., age, BMI, ethnicity, gender, and BP 
status), and exercise intervention (i.e., FITT, supervision, and adherence). 
In summary, the purpose of this meta-analysis was to circumvent the limitations 
of the literature on candidate gene association exercise studies by increasing the sample 
size to detect genetic associations with the BP response to AE. Despite the emergence of 
the AGT M235T polymorphism as a promising variant to explore in future research, the 
clinical sample features of age, gender, and resting BP explained most of the variability 
in the BP response to AE. Our findings reinforce the notion that most genetic variants 
explain only a small amount of variability in the response of health/fitness phenotypes to 
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exercise, if any. Our findings also indicate that research efforts seeking to explain the 
variability of health/fitness phenotypes to exercise such as BP should explore clinical 
features known to influence the phenotype of interest, as well as the multiple levels of 
gene regulation using high throughput screening in larger, more ethnically diverse 
samples of men and women with HTN. 
 APPENDIX A 
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PubMed Search Strategy 
 
 
Blood Pressure: ("mean arterial" OR "blood pressure"[mesh] OR "blood pressure" OR "blood 
pressures" OR "arterial pressure" OR "arterial pressures" OR hypertension OR hypotension OR 
normotension OR hypertensive OR hypotensive OR normotensive OR "systolic pressure" OR 
"diastolic pressure" OR "pulse pressure" OR "venous pressure" OR "pressure monitor" OR 
hypotension OR "pre hypertension" OR "bp response" OR "bp decrease" OR "bp reduction" OR 
"bp monitor" OR "bp monitors" OR "bp measurement")  
 
Exercise: ("exercise"[mesh] OR exercise OR exercises OR running[mesh] OR "bicycle" OR 
"bicycles" OR "bicycling" OR walking[mesh] OR treadmill* OR "weight lifting" OR "weight 
training" OR "weight bearing" OR "resistance training" OR "strength training" OR "endurance 
training" OR "speed training" OR "training duration" OR "training frequency" OR "training 
intensity" OR "aerobic endurance")  
 
Randomized Control Trial: ("randomized controlled trial"[pt] OR "nonrandomized controlled" 
OR "nonrandomized control" OR controlled clinical trial[pt] OR "randomized controlled 
trial"[publication type] OR random allocation[mh] OR clinical trial[pt] OR "comparative study" 
OR "comparative studies" OR clinical trials[mh] OR "clinical trial"[tw] OR "latin square"[tw] 
OR random*[tw] OR research design[mh:noexp] OR "comparative study"[publication type] OR 
"evaluation studies"[publication type] OR "prospective studies"[mh] OR "cross-over 
studies"[mh] OR "control"[tw] OR "controlled"[tw])  
 
Gene: ("gene" OR "genes" OR "genotype" OR "genotypes" OR "snp" OR polymorphism* OR 
"DNA" OR "minor allele" OR "minor alleles" OR "single nucleotide polymorphism" OR "single 
nucleotides polymorphisms" OR genetic*)  
 
Exclusion Search Terms: ("DASH"[tiab] OR "cancer" OR "neoplasms" OR "review"[pt] OR 
"fibromyalgia" OR "alzheimers" OR "alzheimer" OR "pregnant" OR "pregnancy" OR 
"obesity/drug therapy"[mesh] OR "diet therapy"[mesh] OR "diet therapy"[subheading] OR 





OR "dehydrated" OR "dietary salt" OR "epilepsy" OR "influenza" OR "flu" OR "pneumonia" 
OR "septicemia" OR "hiv" OR "Acquired Immunodeficiency Syndrome" OR "meningitis" OR 
"substance abuse" OR "alcoholism" OR "drug abuse" OR "Cross-Sectional Studies"[MeSH 
Terms] OR "Prospective Studies"[MeSH Terms] OR "epidemiology"[Subheading]) 
 
Abbreviations: Medical Subject Heading=Mesh; MeSH Terms=mh; Text Word=tw; 





Candidate Gene Meta-Analysis Selection Criteria Checklist 
   
Study ID: __________ 
  Coder: __________ 
 
Candidate Gene Meta-Analysis Selection Criteria 
Inclusion Criteria 





Trials CANNOT include any of the 
following: 
An acute and/or chronic aerobic exercise 
intervention 
 
A case-control, cross-sectional, or family 
based study design (Note: A non-exercise 
control or comparison group is required for all 
trials; and, a non-exercise control group or 
session is required for all acute trials) 
 
Exercise intervention(s) involve all parameters 
of the FITT (Note: all FITT parameters 










A pre-and post-exercise blood pressure 
measurement by genotype 
 
A candidate gene polymorphism(s) 
 










































Persons on weight-loss drugs, or 



















Prospective studies  
 













































CANDIDATE GENE ASSOCIATION STUDIES ON THE BLOOD PRESSURE 
RESPONSE TO ACUTE AND CHRONIC AEROBIC EXERCISE 
META-ANALYSIS CODING FORM 
 
Revised 8 April 2011 
 
For any missing or unreported data, indicate with “.” 
 
 




(V2) ID   ________ Study ID # Study Citation (AuthorYearJournal):  
 
    ________________________________    
    (Use journal format from PubMed) 
  
(V3) PUB_YR  ________ Publication year (consider this missing if unpublished) 
  
(V4) DATA  ________ Estimated year of data collection (earliest date for data collection or manuscript 
    submission/publication; if unpublished and date unknown, use year manuscript was acquired; 
    for dissertation or thesis, use year)  
 
(V5) LANG.  ________ Language of publication 
    1=English       
    2=Spanish 
    3=Japanese 
    4=Other, specify: __________________________ 
 
(V6) SOURCE  ________ Source: 
    1=Journal  
    2=Book  
    3=Thesis/Dissertation  
    4=Conference Paper  
    5=Unpublished Document 
 
(V7) SCORE  ________ Impact Score of the Journal (use ISI Web of Knowledge journal citation reports) 
 
 




Sample Characteristics (proportion: 0.0- 1.0) 
 
(V9) ETH  ________ Ethnicity reported? 1 = Yes; 0 = No   
(V10) PROP_WH ________ Proportion White; if whole number available: ______ 
(V11) PROP_BLK ________ Proportion Black; if whole number available: ______ 
(V12) PROP_HISP ________ Proportion Latino/Hispanic; if whole number available: ______ 
(V13) PROP_CARIB ________ Proportion Caribbean; if whole number available: _____ 
(V14) PROP_ASIAN ________ Proportion Asian; if whole number available: ______ 
(V15) PROP_MIX ________ Proportion Mixed/other; if whole number available: ______ 





(V17) PROP_HS ________ Proportion high school; if whole number available: ______  
(V18) PROP_COL ________ Proportion college; if whole number available: ______  
(V19) PROP_GRAD ________ Proportion graduate school; if whole number available: ______ 
(V20) SES  ________ SES reported? 1 = Yes; 0 = No 
(V21) PROP_LOW ________ Proportion of low SES Low (< 25k) 
(V22) PROP_MID ________ Proportion of middle SES (25k-100k) 
(V23) PROP_HIGH ________ Proportion of high SES (>100k)  
 
(V24) #FEMALE ________ # of females in sample 
 
(V25) REGION  ________ Region of sample 
 1=American city: __________________ 
 2=Other U.S. general region (city not specified):  __________________ 
 3=Canada  (city: _______________________) 
 4=Europe (city: _______________________) 
 5=South or Central America, Mexico, Caribbean (city: _______________________) 
 6=Africa  (city: _______________________) 
 7=Asia (city: _______________________) 
 8=Australia (city: _______________________) 
 
(V26) US_ZIP  ________ Zip Code (US Only) _____________  
 
(V27) POP  ________ Population 
  0=Not reported 
 1=School or college 
  2=Community, not currently institutionalized; specify source  (e.g., cancer clinic including 
University cancer treatment facilities): 
________________________________________________________ 




(V28) ________ Notes on sample characteristics relevant to coding  
______________________________________________________________________________________ 
   
Risk Characteristics (if SEM, change to SD; SD= SEM *√; use DSTAT to poole variances if applicable) 
 
(V29) AGE  ________ Mean age of total sample (years)  
(V30) AGE_SD  ________ SD for age (years) 
 
(V31) HT  ________ Mean height of total sample (cm)  
(V32) HT_SD  ________ SD of height (cm) 
 
(V33) WT  ________ Mean weight of total sample (kg) 
(V34) WT_SD  ________ SD of weight (kg) 
(V35) WAIST  ________ Mean waist circumference of total sample (cm) 
(V36) WAIST_SD ________ SD of waist circumference (cm) 
 
(V37) W-H  ________ Mean waist-to-hip ratio of total sample 
(V38) W-H_SD  ________ SD of waist-to-Hip Ratio 
(V39) BMI  ________ Body mass index of total sample (BMI, kg•m-2)  
    (if calculating, use NHLBI equation) 
(V40) BMI_SD  ________ SD of BMI 
(V41) BMI_NORM ________ Proportion normal weight (18.5-24.9) 
(V42) BMI_OVER ________ Proportion overweight (25.0-29.9) 





(V44) BMI_OBESE2 ________ Proportion obese, Class II (35.0-39.9)  
(V45) BMI_OBESE3 ________ Proportion obese, Class III (≥ 40.0)  
(V46) BF%  ________ Mean value of body composition of total sample (Body Fat %) 
(V47) BF%_SD  ________ SD of body fat % 
(V48) BF%_ASS. ________ Method of body fat % assessment 
    1=Skinfold thickness  
    2=Hydrostatic weighing 
    3=Bioelectrical impedance, specify: _________________ 
    4=Air displacement plethysmography, specify: _________________ 
    5=Dual energy x-ray absorptiometry (DEXA), specify: _________________ 
    6=Other, specify: __________________ 
 
(V49) PROP_HD ________ Proportion of total sample with history of heart disease in immediate 
family members before age 55; if whole number available ______  
 
(V50) PROP_ HTN ________ Proportion of total sample with hypertension in immediate family 
    members; if whole number available ______  
 
(V51) DISEASE ________ Known disease(s) or chronic condition(s) of total sample 
    0= Subjects were free of disease(s)/chronic condition(s) 
    1= Pre-Hypertension 
    2= Hypertension, specify stage: __________________________ 
    3= Cardiovascular disease(s) (coronary artery disease, peripheral artery disease, 
    congestive heart failure, myocardial infarction) 
    4= Stroke 
    5= Diabetes 
    6= Metabolic Syndrome (MetS) 
    7= Arthritis 
    8= Other, specify: __________________ 
    9= Multiple, specify #s:__________________ 
 
(V52) CHF  ________ If congestive heart failure, indicate functional classification  
    (according to NYHA criteria) 
    0= Not applicable 
    1= Class I 
    2= Class II 
    3= Class III 
    4= Class IV 
    5= Multiple, specify #’s______________ 
 
(V53) MetS  ________ If Metabolic Syndrome (MetS), what grouping system was used to define  
    0= Not applicable 
    1= Specify: __________________ 
    
(V54) PROP_SED ________ Proportion of sample that was sedentary (≤ 2d•wk-1 of regular physical 
        activity); if whole number available ______ 
 












(V56) MED_TYPE ________ Medication Type 
    1= β Blockers 
    2= Nitrates 
    3= Calcium Channel Blockers 
    4= Angiotensin Converting Enzyme (ACE) Inhibitors 
    5= Diuretics 
    6= Vasodilators, non-adrenergic 
    7= NSAIDs 
    8= Aspirin 
    9= Other, specify: ________________ 
    10= Multiple, specify numbers: ________________ 
 
(V57) O/C_USE ________ Oral Contraceptive use (0=No, 1= Yes) 
 
(V58) CAFFEINE_USE ________ Number of days per week of caffeine consumption 
(V59) CAFFEINE_DR ________ Number of caffeinated beverages per day 
(V60) CAFFEINE_WK ________ Number of caffeinated beverages per week 
(V61) PROP_CAF ________ Proportion of sample with regular caffeine consumption; if whole  
     number available ______ 
 
(V62) ETOH_USE ________ Number of days per week of alcohol consumption 
(V63) ETOH_DR ________ Number of alcoholic drinks per day 
(V64) ETOH_WK  ________ Number of alcoholic drinks per week 
(V65) PROP_ETOH ________ Proportion of sample reporting regular alcohol consumption; if whole 
        number available ______ 
 
(V66) SMOKING  ________Currently smoking, or smoked within last 6 months (0= No, 1= Yes) 
(V67) SMOKING_YRS   ________Number of years smoking 
(V68) SMOKE_PACK  ________Number of packs per week (calculate in data base pack/ year) 
(V69) PROP_SMOKE  ________Proportion of sample currently smoking or smoked within the last 6 
      months? ; if whole number available ______ 
 




Methods & Design 
 
(V71) RECRUIT  ________ Recruitment method 
 1=Self-selected from community (via flyers, community centers, etc.) 
  2=Recruited through clinical contact  
  3=Recruited through hospital 
  4=Other, specify: __________ 
    
(V72) CON_GRP ________ Type of control group used 
 1= Random assignment of individuals to conditions including a non-exercise control 
 group 
 2= Random assignment of individuals to conditions including a non-exercise control               
session 
3= Random assignment of individuals to conditions including a control group of 
stretching or yoga 
4= Other, specify: 
______________________________________________________________________ 
 
(V73) #F/U   ________ Number of follow-ups: ______________________________  





(V74) F/U_INT.   ________ Interval of follow-ups: _______________________________  
    (0=acute,1= pre/post design)  
 (# of follow-ups refer to the assessments completed post intervention, i.e. 3, 6, 12 months post study) 
  






(V76) MECH  ________ Mechanism 
    0= None reported 
    1= Genetic 
    2= Neural 
    3= Vascular 
    4= Renal  
    5= Other, specify:________________ 
    6= Multiple, specify #s:___________ 
 




(V78) BIO PATH ________ Major Biological Pathway 
0= None  
1= Renal/Renin Angiotensin System 
2= Sympathetic Nervous System 
3= Nitric Oxide Synthase Pathway 
4= Energy Metabolism 
5= Inflammation/Thrombosis/ Hemostasis 
6= Other 
 










Downs and Black tool (Downs and Black 1998) 
  
 





































10. Have actual probability values been reported (e.g. 0.035 rather than <0.05) for the main outcomes except where the 






All the following criteria attempt to address the representativeness of the findings of the study and whether they may be 
generalised to the population from which the study subjects were derived. 
 
11. Were the subjects asked to participate in the study representative of the entire population from which they were recruited? 
Yes 1 
No 0 
Unable to determine 0 
 








Unable to determine 0 
 




Unable to determine 0 
 
Internal validity - bias 
 
14. Was an attempt made to blind study subjects to the intervention they have received? 




Unable to determine 0 
 




Unable to determine 0 
 
16. If any of the results of the study were based on “data dredging”, was this made clear? 
Yes 1 
No 0 
Unable to determine 0 
 
17. In trials and cohort studies, do the analyses adjust for different lengths of follow-up of patients, or in case-control studies, is 
the time period between the intervention and outcome the same for cases and controls? 
Yes 1 
No 0 
Unable to determine 0 
 
18. Were the statistical tests used to assess the main outcomes appropriate? 
Yes 1 
No 0 
Unable to determine 0 
 
19. Was compliance with the intervention/s reliable? 
Yes 1 
No 0 
Unable to determine 0 
 
21. Were the patients in different intervention groups (trials and cohort studies) or were the cases and controls (case-control 
studies) recruited from the same population? 
Yes 1 
No 0 
Unable to determine 0 
 
22. Were study subjects in different intervention groups (trials and cohort studies) or were the cases and controls (case-control 
studies) recruited over the same period of time? 
Yes 1 
No 0 
Unable to determine 0 
 







Unable to determine 0 
 
24. Was the randomised intervention assignment concealed from both patients and health care staff until recruitment was 
complete and irrevocable? 
Yes 1 
No 0 
Unable to determine 0 
 
25. Was there adequate adjustment for confounding in the analyses from which the main findings were drawn? 
Yes 1 
No 0 
Unable to determine 0 
 
26. Were losses of patients to follow-up taken into account? 
Yes 1 
No 0 




27. Did the study have sufficient power to detect a clinically important effect where the probability value for a difference being 
due to chance is less than 5%? Sample sizes have been calculated to detect a difference of x% and y%. 
 
 Size of smallest intervention group  
A <n1 0 
B n1- n2 1 
C n3- n4 2 
D n5- n6 3 
E n7- n8 4 











(V81) EXPERIMENT ________ Experimental condition(s) 
    Independent groups (between-subjects design; participant only experiences one 
condition) 
    1= Non-exercise control/comparison + one experimental group 
    2= Non-exercise control/comparison + two experimental groups 
    3= Non-exercise control/comparison + three experimental groups 
    Non-Independent groups (within-subjects design; participant experiences more than 
one condition) 
    4= Non-exercise control/comparison + one experimental condition 
    5= Non-exercise control/comparison + two experimental conditions 








(V82) EXP_SETTING ________ Setting of Experiment/ Intervention 
    1= Hospital 
    2= Clinic 
    3= Academic Research Laboratory 
    4= Fitness Center, Gym 
    5= Other, specify: _____________________________ 
    6= Multiple, specify: _____________________________ 
 
(V83) PERSP  ________ Theoretical perspective: 
                   0= None specified 
  1= Psychological 
    2= Other, specify __________________________ 
 
(V84) BEHAV_TECH ________ Behavioral technique used in study? 
    0= None 
1= Yes, specify (positive reinforcement, modeling, contingency management, exercise 
and lifestyle information provided, etc.) 
     
(V85) INTER_LVL ________ Level of intervention used in the study 
 1=Primarily one-on-one (e.g., individual counseling sessions) 
 2=Small group processes (interaction between leader and group, and group members) 
 3=Supervised session(s) 
 4=Unsupervised session(s) 
 5=Multiply, specify #’s: ________________________________ 
 




Candidate Gene Polymorphisms 
 
(V87) QUANT_GENES ________ Number of candidate genes examined  
 







(V89) QUANT_SNP ________ Number of SNPs examined  
 




    ________ 
 























(V94) DESIGN ________Study design  
  1=Case-control 
  2=Cross-sectional 
3=Family-based 
(V95) SNP_RATION ________ Rationale for SNP selection  
1=Allele frequency 
2=Literature search 
3=Follow-up to GWAS 
 





(V97) TECH  ________ Sampling technique(s) 
 1=Buccal swab 
 2=Blood 
 











(V100) MAJ_FREQ ________ Major Allele Frequency  
(V112a) 
 1=Stated in paper 
 2=Calculated from paper 
 3=Obtained from authors 
 4=Unknown  
 (V112b) ________ Case frequency 
 (V112c) ________ Control frequency 
 
(V101)  MIN_FREQ ________ Minor Allele Frequency 
(V112a) 
 1=Stated in paper 
 2=Calculated from paper 
 3=Obtained from authors 
 4= Unknown  





 (V112c) ________ Control frequency 
 
(V102) HWE ________ Hardy Weinberg Equilibrium 
 1=Yes 
 2=No 
 3=Not stated  
 
(V103) LD ________ Linkage Disequilibrium 









CANDIDATE GENE CODING INFORMATION 
 




List interventions from LOWEST intensity to HIGHEST 
intensity 





(V104) Subgroup (i.e. men, women, hypertensive, normotensive, white, black, etc.), specify:  
________________(0=Not applicable) 
(V105) GENE_NAME Name of candidate genes examined: ________________ 
(V106) SNP_TEST Specific SNP examined (include RS #’s if available): ________________ 
(V107) CHROM_NUMB Chromosome number________________ 
(V108) CHROM_BAND Chromosome band________________ 
(V109) CHROM_SUB Chromosome sub-band________________ 
(V110) FUNCT Function (1=missense, 2=nonsense, 3=coding synonymous, 4=neargene-3, 5=neargene-5, 6=3’-
UTR, 7=5’-UTR, 8=intron) ________________ 
(V111)  # PART_BEG  
# of participants at beginning of intervention 
    
(V112) # PART_END 
# of participants at end of intervention  
    
(V113) # PART_LOST 
# of participants lost during intervention 
    
(V114) ADHERENCE 








    
(V115) EX_INTENSITY 
Exercise intensity (specify method used to 
calculate intensity) 0=Control/Non-exercise 
comparison group/session (Note. If ranges are 
reported, compute the mean or average value) 
    
(V116) EX_TYPE 
Exercise modality  
0=Control (non-exercise comparison) 
1= Aerobic, treadmill 
2= Aerobic, cycle ergometer 
3= Other, specify: _______________ 
4= Multiple, specify numbers: ___________ 
    
(V117) EX_LENGTH 
Length of intervention (weeks) 0=Acute 
    
(V118) FREQ_SESSION 
Exercise Frequency (sessions per week) 
0=Acute 
    
(V119) FREQ_WK 
Exercise Frequency (min per week) 0=Acute 
    
(V120) EX_TOTAL 
Total Exercise Duration (min per week) 






Warm-up (min per session) 
    
(V122) EX_TIME 
Exercise (min per session) 
    
(V123) EX_C/D 
Cool down (min per session) 
    
(V124) VAR_ALTER 
Study Variable manipulated 






6=Exercise vs. Control 
7=Multiple, specify #s: _______________ 
    
(V125) ∆VO2 
VO2max change (specify method used to 
calculate intensity) 0= Acute 
    
(V126) BP_ASSESS 
BP Measurement  
1=Manual  
2=Ambulatory (ABP), hrs monitored: _____ 
3=Automated 
4=Multiple, specify #s__________ 
    
(V127) BP_POSITION 




4=Multiple, specify #s________________ 
    
(V128) BP_BASE 
Duration prior to baseline BP assessment 
(min) 
(insert continuous variable, or “.” if none or 
missing) 
    
(V129) SBP_INITIAL 
Initial SBP (mmHg) 
    
(V130) INITIAL_SD 
SD of Initial SBP (mmHg) 
    
(V131) SBP_POST 
Post SBP (mm Hg) 
    
(V132) POST_SD 
SD of Post SBP (mmHg) 
    
(V133) SBP_AB∆ 
Absolute change SBP (mmHg) 
(if not calculated, insert “.”and calculate in 
spreadsheet) 
    
(V134) AB∆_SD 
SD of Absolute change SBP (mmHg) 
    
(V135) DBP_INITIAL 
Initial DBP (mmHg) 
    
(V136) INITIAL _SD 
SD of Initial DBP (mmHg) 
    





Post DBP (mmHg) 
(V138) POST_SD 
SD of Post DBP (mmHg) 
    
(V139) DBP_AB∆  
Absolute change DBP (mmHg) 
(if not calculated, insert “.”and calculate in 
spreadsheet) 
    
(V140) AB∆_SD 
SD of Absolute change DBP (mmHg) 
    
(V141) BP_POST 
Time of Post BP assessment (min) 
(insert continuous variable, or “.” if none or 
missing) 
    
(V142) MAP 
MAP (mm Hg) (if not calculated, insert 
“.”and calculate in spreadsheet) 




List interventions from LOWEST intensity to HIGHEST 
intensity 





(V143) Subgroup (i.e. men, women, hypertensive, normotensive, white, black, etc.), specify: ________________ 
(0=Not Applicable) 
(V144) GENE_NAME Name of candidate genes tested: ________________ 
(V145) SNP_TEST Specific SNP examined (include RS #’s if available): ________________ 
(V146) CHROM_NUMB Chromosome number________________ 
(V147) CHROM_BAND Chromosome band________________ 
(V148) CHROM_SUB Chromosome sub-band________________ 
(V149) FUNCT Function (1=missense, 2=nonsense, 3=coding synonymous, 4=neargene-3, 5=neargene-5, 6=3’-
UTR, 7=5’-UTR, 8=intron) ________________ 
(V150) #PART_BEG  
# of participants at beginning of intervention 
    
(V151) #PART_END 
# of participants at end of intervention  
    
(V152) #PART_LOST 
# of participants lost during intervention 
    
(V153) ADHERENCE 








    
(V154) EX_INTENSITY 
Exercise intensity (specify method used to 
calculate intensity) 0=Control/Non-exercise 
comparison group/session (Note. If ranges are 
reported, compute the mean or average value) 
    
(V155) EX_TYPE 
Exercise modality  
0=Control (non-exercise comparison) 
1=Dynamic resistance training (free weights) 
2=Dynamic resistance training (machine 






3=Isometric resistance training  
4=Other, specify: _______________ 
5=Multiple, specify numbers: ___________ 
(V156) EX_LENGTH 
Length of intervention (weeks) 0=Acute 
    
(V157) FREQ_SESSION 
Exercise Frequency (sessions per week) 
0=Acute 
    
(V158) FREQ_WK 
Exercise Frequency (min per week) 0=Acute 
    
(V159) EX_TOTAL 
Total Exercise Duration (min per week) 
    
(V160) EX_W/UP 
Warm-up (min per session) 
    
(V161) EX_TIME 
Exercise (min per session) 
    
(V162) EX_C/D 
Cool down (min per session) 
    
(V163) EX_SETS 
Total # of sets performed in session 
    
(V164) EX_REPS 
Total # of reps performed in one set 
    
(V165) VAR_ALTER 






5=Exercise volume  
6=Exercise vs. Control 
7=Multiple, specify #s: _______________ 
    
(V166) ∆VO2 
VO2max change (specify method used to 
calculate intensity) 0=Acute 
    
(V167) BP_ASSESS 
BP Measurement  
1=Manual  
2=Ambulatory (ABP), hrs monitored: _____ 
3=Automated 
4=Multiple, specify #s__________ 
    
(V168) BP_POSITION 




4=Multiple, specify #s________________ 
    
(V169) BP_BASE 
Duration prior to baseline BP assessment 
(min) 
(insert continuous variable, or “.” if none or 
missing) 
    





Initial SBP (mmHg) 
(V171) INITIAL_SD 
SD of Initial SBP (mmHg) 
    
(V172) SBP_POST 
Post SBP (mmHg) 
    
(V173) POST_SD 
SD of Post SBP (mmHg) 
    
(V174) SBP_AB∆ 
Absolute change SBP (mmHg) 
(if not calculated, insert “.”and calculate in 
spreadsheet) 
    
(V175) AB∆_SD 
SD of Absolute change SBP (mmHg) 
    
(V176) DBP_INITIAL 
Initial DBP (mmHg) 
    
(V177) INITIAL _SD 
SD of Initial DBP (mmHg) 
    
(V178) DBP_POST 
Post DBP (mmHg) 
    
(V179) POST_SD 
SD of Post DBP (mmHg) 
    
(V180) DBP_AB∆  
Absolute change DBP (mmHg) 
(if not calculated, insert “.”and calculate in 
spreadsheet) 
    
(V181) AB∆_SD 
SD of Absolute change DBP (mmHg) 
    
(V182) BP_POST 
Time of Post BP assessment (min) 
(insert continuous variable, or “.” if none or 
missing) 
    
(V183) MAP 
MAP (mmHg) (if not calculated, insert 
“.”and calculate in spreadsheet) 






















 Statistical Analyses 
 
 
Statistical Variable: Homozygous 
Common Genotype (AA) 
 
Control Exercise group 1 (specify: ______________) 
Exercise group 2 
(specify: 
______________) 
(V184) ____Method of analysis (1=Dominant model, 2=Recessive model, 3=Risk allele) 
 
(V185) ____Multiple testing correction (1=Yes, 2=Yes but questionable, 3=No) 
 
(V186)  SBP Mean & SD  
               (0=if not calculated) 
   
(V187) DBP Mean & SD  
               (0=if not calculated) 
   
(V188) SBP Correlation 
Coefficient  
 (0=if not calculated) 
   
(V189) DBP Correlation 
Coefficient  
 (0=if not calculated) 
   
(V190) SBP Odds ratio 
  (0=if not calculated) 
   
(V191) DBP Odds ratio 
  (0=if not calculated) 
   
(V192) SBP R-squared value  
 (0=if not calculated) 
   
(V193) DBP R-squared value  
 (0=if not calculated) 
   
(V194) SBP Chi-Squared Result  
 (0=if not calculated) 
   
(V195) DBP Chi-Squared Result  
 (0=if not calculated) 
   
(V196) SBP P-Value 
 (0=if not calculated) 
   
(V197) DBP P-Value 
 (0=if not calculated) 
   
(V198) SBP F Statistic 
 (0=if not calculated) 
   
(V199) DBP F Statistic 
 (0=if not calculated) 
   
(V200) SBP Confidence Interval  
 (0=if not calculated) 
   
(V201) DBP Confidence Interval 
 (0=if not calculated) 
   
(V202) SBP Other statistical 
outcome, specify:_______ 
   
(V203) DBP Other statistical 
outcome, specify: _______ 
   
 












Heterozygous Genotype (AB) 
 
Control Exercise group 1 (specify:______________) 
Exercise group 2 
(specify:______________) 
(V205) ____Method of analysis (1=Dominant model, 2=Recessive model, 3=Risk allele) 
 
(V206) ____Multiple testing correction (1=Yes, 2=Yes but questionable, 3=No) 
 
(V207)  SBP Mean & SD  
               (0=if not calculated) 
   
(V208) DBP Mean & SD  
               (0=if not calculated) 
   
(V209) SBP Correlation 
Coefficient  
 (0=if not calculated) 
   
(V210) DBP Correlation 
Coefficient  
 (0=if not calculated) 
   
(V211) SBP Odds ratio 
  (0=if not calculated) 
   
(V212) DBP Odds ratio 
  (0=if not calculated) 
   
(V213) SBP R-squared value  
 (0=if not calculated) 
   
(V214) DBP R-squared value  
 (0=if not calculated) 
   
(V215) SBP Chi-Squared 
Result  
 (0=if not calculated) 
   
(V216) DBP Chi-Squared 
Result  
 (0=if not calculated) 
   
(V217) SBP P-Value 
 (0=if not calculated) 
   
(V218) DBP P-Value 
 (0=if not calculated) 
   
(V219) SBP F Statistic 
 (0=if not calculated) 
   
(V220) DBP F Statistic 
 (0=if not calculated) 
   
(V221) SBP Confidence 
Interval  
 (0=if not calculated) 
   
(V222) DBP Confidence 
Interval 
 (0=if not calculated) 
   
(V223) SBP Other statistical 
outcome, specify: ____ 
   
(V224) DBP Other statistical 
outcome, specify: ____ 
   
 









Homozygous Minor Genotype 
(BB) 
 
Control Exercise group 1 (specify:______________) 
Exercise group 2 
(specify:______________) 
(V226) ____Method of analysis (1=Dominant model, 2=Recessive model, 3=Risk allele) 
 
(V227) ____Multiple testing correction (1=Yes, 2=Yes but questionable, 3=No) 
 
(V228)  SBP Mean & SD  
               (0=if not calculated) 
   
(V229) DBP Mean & SD  
               (0=if not calculated) 
   
(V230) SBP Correlation 
Coefficient  
 (0=if not calculated) 
   
(V231) DBP Correlation 
Coefficient  
 (0=if not calculated) 
   
(V232) SBP Odds ratio 
  (0=if not calculated) 
   
(V233) DBP Odds ratio 
  (0=if not calculated) 
   
(V234) SBP R-squared value  
 (0=if not calculated) 
   
(V235) DBP R-squared value  
 (0=if not calculated) 
   
(V236) SBP Chi-Squared 
Result  
 (0=if not calculated) 
   
(V237) DBP Chi-Squared 
Result  
 (0=if not calculated) 
   
(V238) SBP P-Value 
 (0=if not calculated) 
   
(V239) DBP P-Value 
 (0=if not calculated) 
   
(V240) SBP F Statistic 
 (0=if not calculated) 
   
(V241) DBP F Statistic 
 (0=if not calculated) 
   
(V242) SBP Confidence 
Interval  
 (0=if not calculated) 
   
(V243) DBP Confidence 
Interval 
 (0=if not calculated) 
   
(V244) SBP Other statistical 
outcome, specify: ____ 
   
(V245) DBP Other statistical 
outcome, specify: ____ 
   
 





ExBP Meta-Analysis Quality M-a (Author(s), Year, Journal): Coder: 
 
Question Rationale for Question Score Notes (If Any) 
1. Was an ‘a priori’ design provided? The research question and inclusion criteria should be established before the conduct of the 
review.  Is it stated that these were finalized before commencing the review?  
 
AMSTAR#1-modified 
2. Were population variables defined and 
considered in the methods? 
Blood pressure is related to patient (age, biological sex, ethnicity, BMI) and clinical (chronic 
disease, medication use) variables.  
 
3. Was there duplicate study selection and 
data extraction? 
There should be at least two independent data extractors and a consensus procedure for 




4. Was a comprehensive literature search 
performed? 
At least two electronic sources should be searched. The report must include years and 
databases used (e.g. Central, EMBASE, and MEDLINE). All searches should be supplemented 
by consulting current contents, reviews, textbooks, specialized registers, or experts in the 
particular field of study, and by reviewing the references in the studies found. 
 
AMSTAR#3-modified 
5. Is it possible to replicate the search? The Method or Supplementary Materials should make it possible for a second party to replicate 
the search, including all databases, search terms, and operators. Key words and/or MESH 
terms must be stated or available from the authors and where feasible the search strategy 
should be provided. If authors report MeSH terms were used for searching, they must be stated 
in methods OR provided in supplementary material to be considered a “2.” A note to contact the 
author for complete search strategy is also acceptable. 
 
AMSTAR#3-modified 
6. Did the inclusion criteria permit grey 
literature? 
The authors should state that they searched for reports regardless of their publication type. The 
authors should state whether or not they excluded any reports (from the systematic review), 
based on their publication status, language etc. 
 
AMSTAR#4-modified 
7. Was a list of studies (included and 
excluded) provided? 
A list of included and excluded studies should be provided. A descriptive summary of reasons 
for excluding studies should be provided such as in a QUORUM or PRISMA figure.  
 
AMSTAR#5-modified 
8. Were the characteristics of the included 
studies provided? 
In an aggregated form such as a table, data from the original studies should be provided on the 
participants, interventions and outcomes. The ranges of characteristics in all the studies 
analyzed e.g. age, race, sex, relevant socioeconomic data, disease status, duration, severity, or 
diseases. Data must be presented for each study individually in a table to receive a score of “2” 
simply providing population or study description in the text is not sufficient. 
 
AMSTAR#6 
9. Was FITT defined for each study and 
examined in relation to BP effect sizes? 
Frequency, Intensity, Time and Type (FITT) of exercise define major components of exercise 
and logically relate to BP changes. Results need not show significant moderation patterns.  
 
 
10. Was the scientific quality of the included 
studies assessed and documented? 
‘A priori’ methods of assessment should be provided (e.g., for effectiveness studies if the 
author(s) chose to include only randomized, double-blind, placebo controlled studies, or 
allocation concealment as inclusion criteria); for other types of studies alternative items will be 
relevant. If study quality was assessed and documented with a tool and/ or scale, choose 2; if it 
was discussed in text only, choose 1; if it was not documented at all, choose 0 
 
AMSTAR#7 
11. Was the scientific quality of the included 
studies used appropriately in formulating 
conclusions? 
The results of the methodological rigor and scientific quality of the included studies must be 
considered in the analysis and the conclusions of the review, and explicitly stated in formulating 
recommendations to receive a “2” (i.e., study quality scores related to outcomes, discussion of 
individual study quality and its relation to outcome). Simply stating inclusion of specific study 
design (e.g., RCTs) because they are typically of higher quality is not sufficient.  
 
AMSTAR#8 
12. Did results depend on study quality, 
either overall, or in interaction with 
moderators? 
Studies with higher methodological rigor (e.g., with a scale such as PEDro) should yield clearer 
findings, other factors equal. 
 
 
13. Were the methods used to combine the 
findings of studies appropriate? 
For the pooled results, a test should be done to ensure the studies were combinable, to assess 
their homogeneity (i.e., χ2 for homogeneity or I²). If heterogeneity exists, random-effects 
assumptions should be incorporated and/or the clinical appropriateness of combining should be 
taken into consideration (i.e. is it sensible to combine?). If a test of homogeneity was 
conducted, the X2 or I2 value is reported, and they report the statistical assumptions (i.e., fixed 
vs. random-effects) choose 2; if they report some of the information but not all, choose 1; if they 
do not discuss homogeneity at all, choose 0. 
 
AMSTAR#9-modified 
14. Was the effect size index chosen 
justified, statistically? 
Comparisons of studies’ results may be biased in the face of uncontrolled variables (e.g., 






authors provide ES equation/ explain their ES calculation and relate it to the various study 
designs and methods of reporting results, choose 2; if authors provide ES information but do 
not relate it to various study designs, choose 1; if ES is not discussed at all, choose 0.  
15. Was individual-level meta-analysis used 
for moderator analyses? 
The authors should state whether or not they obtained original data from the study authors 
when performing moderator analyses.  
 
 
16. Were clinical ramifications clearly 
addressed? 
The results and discussion should clearly lend themselves to informing clinical practice in 
relation to particular populations and health problems. Reports must provide clear clinical 
ramification or recommendation (i.e., what does this study add?) Simply re-stating what is 
known in the literature, or introduction material is not adequate. 
 
 
17. Was the likelihood of publication bias 
assessed? 
Asymmetries in effect sizes are examined as evidence of potential publication bias and includes 
a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests 
(e.g., Egger regression test).   
 
AMSTAR#10 
18. Was the conflict of interest stated? Potential sources of support or conflict should be clearly acknowledged in both the systematic 
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